Vanessa Marchant
Overview
Explore the profile of Vanessa Marchant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tejera-Munoz A, Cortes M, Rodriguez-Rodriguez A, Tejedor-Santamaria L, Marchant V, Rayego-Mateos S, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273564
Cellular Communication Network Factor 2 (CCN2) is a matricellular protein implicated in cell communication and microenvironmental signaling. Overexpression of CCN2 has been documented in various cardiovascular pathologies, wherein it may...
2.
Trionfetti F, Montaldo C, Caiello I, Bontempi G, Terri M, Tiberi M, et al.
Front Cell Infect Microbiol
. 2024 Mar;
14:1308362.
PMID: 38476167
Infectious peritonitis is a leading cause of peritoneal functional impairment and a primary factor for therapy discontinuation in peritoneal dialysis (PD) patients. Although bacterial infections are a common cause of...
3.
Marchant V, Trionfetti F, Tejedor-Santamaria L, Rayego-Mateos S, Rotili D, Bontempi G, et al.
Antioxidants (Basel)
. 2023 Dec;
12(12).
PMID: 38136175
Peritoneal dialysis (PD) is a current replacement therapy for end-stage kidney diseases (ESKDs). However, long-term exposure to PD fluids may lead to damage of the peritoneal membrane (PM) through mechanisms...
4.
Trionfetti F, Marchant V, Gonzalez-Mateo G, Kawka E, Marquez-Exposito L, Ortiz A, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982834
Chronic kidney disease (CKD) incidence is growing worldwide, with a significant percentage of CKD patients reaching end-stage renal disease (ESRD) and requiring kidney replacement therapies (KRT). Peritoneal dialysis (PD) is...
5.
Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis
Morgado-Pascual J, Suarez-Alvarez B, Marchant V, Basantes P, Tharaux P, Ortiz A, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613933
Progressive glomerulonephritis (GN) is characterized by an excessive accumulation of extracellular (ECM) proteins, mainly type IV collagen (COLIV), in the glomerulus leading to glomerulosclerosis. The current therapeutic approach to GN...
6.
Rayego-Mateos S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernandez C, Marchant V, Donate-Correa J, et al.
Kidney Int
. 2022 Dec;
103(2):282-296.
PMID: 36470394
Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney disease and associated morbidity and mortality. Preclinical research has demonstrated the involvement of inflammation in its...
7.
Rodrigues-Diez R, Tejera-Munoz A, Orejudo M, Marquez-Exposito L, Santos-Sanchez L, Rayego-Mateos S, et al.
Nefrologia (Engl Ed)
. 2022 Sep;
41(3):244-257.
PMID: 36166242
Interleukin-17A (IL-17A) is a proinflammatory cytokine produced by cells of the immune system, predominantly Th17 and γδ lymphocytes. In this paper, we review the role of IL-17A in the pathogenesis...
8.
Opazo-Rios L, Tejera-Munoz A, Soto Catalan M, Marchant V, Lavoz C, Fontao S, et al.
Front Pharmacol
. 2022 Apr;
13:778776.
PMID: 35370692
Diabetic nephropathy (DN) is the main leading cause of chronic kidney disease worldwide. Although remarkable therapeutic advances have been made during the last few years, there still exists a high...
9.
Tejedor-Santamaria L, Morgado-Pascual J, Marquez-Exposito L, Suarez-Alvarez B, Rodrigues-Diez R, Tejera-Munoz A, et al.
Pharmaceuticals (Basel)
. 2022 Feb;
15(2).
PMID: 35215234
Crescentic glomerulonephritis is a devastating autoimmune disease that without early and properly treatment may rapidly progress to end-stage renal disease and death. Current immunosuppressive treatment provides limited efficacy and an...
10.
Rayego-Mateos S, Morgado-Pascual J, Lavoz C, Rodrigues-Diez R, Marquez-Exposito L, Tejera-Munoz A, et al.
Biomolecules
. 2022 Feb;
12(2).
PMID: 35204752
Cellular communication network-2 (CCN2), also called connective tissue growth factor (CTGF), is considered a fibrotic biomarker and has been suggested as a potential therapeutic target for kidney pathologies. CCN2 is...